An evidence-based review was made of the systematic review published in the Annals of Internal Medicine regarding the guidelines for screening asymptomatic women for breast cancer in the United States. The US Preventive Services Task Force's publication does not provide enough detail in the methodology to support a rigorous systematic review as outlined by both the PRISMA statement and the AMSTAR measurement tools. Several points within the task force's statement are questioned because of the lack of research that was needed to draw these conclusions. An addendum is requested to better determine the methods used to conduct the systematic review as well as renewed research using digital mammography and/or a multimodality approach to screening women for breast cancer.
In early November 2009, the US Preventive Services Task Force (USPSTF) published a report in the Annals of Internal Medicine discussing screening techniques for the early detection of breast cancer. The USPSTF has described its work as a systematic review that provided guidelines for the screening and early detection of breast cancer. 1 When the report was released, only a few isolated portions became the focus of the national news media, quickly garnering tremendous public attention. In the interest of providing sonography professionals with the information needed to ensure appropriate evidence-based practice, this review contains a complete evaluation of the report within the context of evidence-based practice. The USPSTF's review of specific published research EDITORIAL REVIEW on select screening techniques used to detect breast cancer, covered film screen mammography (FSM), clinical breast examinations (CBEs), self breast examinations (SBEs), digital mammography (DM), and magnetic resonance imaging (MRI).
Evidence-Based Review
An evidence-based review requires that the manner in which the USPSTF's report was executed be properly described and placed in a hierarchy of scientific impact. The first requirement is to classify the research executed by the USPSTF and verify it as a systematic review of published literature on the five screening modalities previously listed. A systematic review is considered to be one of the highest levels of research evidence and is only exceeded by a meta-analysis ( Figure 1 ). Hierarchy of evidence is used to relate published medical information. A systematic review is defined as a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, as well as to collect and analyze data from the studies that are included in the review. 2 Minimally, a rigorously conducted systematic review needs to specify the methods employed for selecting published articles, describe reviewer bias, and describe how the results were analyzed. 3 In the task force's report, the reported methodology was to update its 2002 report by using other systematic reviews, meta-analyses, recently published literature, and data from the Breast Cancer Surveillance Consortium from 2000-2005. 1 Although publications were sorted and selected, the final set of articles used was not specifically listed in the report. Several evaluative tools are available to ensure that systematic reviews are properly executed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement is an example of a rigorous 27-item checklist that can be used for appraisal of published systematic reviews and is best used at the formative stage of designing a study. 3 The Assessment of Multiple Systematic Reviews (AMSTAR) is a measurement tool that can be used to develop a systematic review methodology based on 11 items. 4 Using both the PRISMA and AMSTAR checklists, the USPSTF's systematic review fell short with a score of 7/27 and 1/11, respectively. These low methodological scores place in question the rigor used in developing the report, limiting the report to a review of literature instead of a formal systematic review. This reduces the overall scientific impact of the task force's report to a much lower level in the hierarchy of evidence.
The USPSTF Report
Even though the methodology used by the USPSTF is not clear and the level of evidence is questionable, the proposed recommendations have been highly publicized. It is important to clearly restate the findings rather than succumb to fragments of the report that have been communicated out of context. The USPSTF has proposed these guidelines:
1. Routine screening mammography in women aged 40 to 49 years of age should not be conducted; rather, this process should be biennial at ages 50 to 74 years. 2. A lack of published evidence exists currently to provide a guideline for providing screening mammography for women older than 75 years of age. 3. A lack of evidence exists for assessing the benefits or harms of using CBEs for women 40 years and older. 4. Self breast examination is not recommended to be taught to women by clinicians, as it is not a sensitive technique and raises a woman's level of anxiety.
A lack of published evidence exists currently to
provide a guideline about benefits or harms associated with digital mammography or MRI instead of FSM. 
USPSTF Guideline Evaluation
The first recommendation by the USPSTF was made based on a literature review of FSM, which is quickly being replaced in most medical facilities. The replacement of FSM with DM is being done to increase image resolution with minimal radiation exposure to the patient. The task force was concerned that FSM could contribute to "overdiagnosis" and radiation exposure. These factors were considered to be a moderate risk for every age group but to be more significant in women 40 to 50 years of age. 1 It is important to point out that this guideline is based on screening patients with FSM, and it does not include the use of follow-up diagnostic mammography images that are typically ordered. Spot compression or magnification mammography images is frequently used to provide higher resolution and raise the sensitivity and specificity of the screening mammogram. 5 The USPSTF report does not address diagnostic mammography views used as a followup to a screening mammography examination.
The next recommendation is that not enough published research exists about the use of screening mammography for women 75 years and older. Again, the balance between benefit and harm to the patient could not be determined. 1 This is not surprising as breast cancers in older women grow slowly and often are discovered at advanced stages; therefore, screening mammography is considered not necessary. Older women also have demonstrated a low level of participation in screening mammography because of their belief that they have outlived their risk. It is generally understood that the risk of breast cancer increases with age. 5, 6 The third recommendation by the task force was that not enough published research exists to determine the benefit or harm that could be attributed to using CBEs with women 40 years and older beyond screening mammography. CBE has been an important technique for clinicians to determine the physical characteristics of palpable breast masses, especially in those younger women with dense breasts. It is important to remember that the task force is calling for more research to provide a clinical guideline, not to stop using this manual technique for assessing the texture of the tissue or the characteristics of a palpable mass.
The next recommendation was to cease teaching SBE to women, as it has a low sensitivity and specificity for detecting breast cancer and can raise the anxiety of patients. The authors again addressed SBE as a solo technique when in fact it has rarely been advocated to be used alone as a screening technique and, in many ways, has been used to provide women with a higher sense of awareness of the changes in their breast tissue.
The final and perhaps the most overlooked recommendation made by the USPSTF is that because of the innovative nature of digital mammography and breast MRI, no specific recommendation could be made. The task force stated that DM and MRI, used as a replacement for FSM, could not be assessed as the benefit versus harm has not been researched properly. 1 The task force deemed both of these techniques to be expensive and generated a poor cost-benefit ratio; however, because the report states that research is not available to review the sensitivity and specificity of these tools, these statements cannot be reasonably made, and the true cost-benefit ratio remains unknown.
Until DM and MRI are selected as screening and diagnostic modalities of choice, the sensitivity and specificity, as well as the true cost-benefit, cannot be addressed adequately. Interestingly, the task force made no comment on the additive benefit of using DM, diagnostic mammography views, breast sonography, and MRI to provide a refined diagnosis. Research conducted by Berg et al. 7 of 111 women with invasive breast cancer found that MRI was individually more sensitive than mammography for this type of cancer. They also noted that in those women with breast tissue, primarily composed of adipose (fatty tissue), breast sonography and MRI were superior for detecting invasive breast cancer compared to mammography. Their overall data demonstrated that combining CBE, mammography, and MRI was the most sensitive combination for overall detection of invasive breast cancer. 7 Although this was a cohort of women with disease, this type of study has to be conducted with asymptomatic women to be able to extol the benefits of a combined approached to screening for all types of breast cancer.
One of the key components of this report was the use of population models to make the determination of the benefit of screening techniques to isolate a true-positive breast cancer case. The USPSTF referred to a randomized control trial's model about the number of women it would need to screen to save one woman's life, comparing 1904 women aged 40 to 49 years to 1339 women aged 50 to 59 years. 8 Although the number of women needed to screen is very comparable, based on the increased incidence of breast cancer in older women, the task force chose to advocate screening in older women. This generalization places women 40 to 49 years of age at risk for those early cellular changes that have been identified with biopsy as atypical ductal hyperplasia (ADH). 6 ADH raises the risk of breast cancer four to five times over the generalized population, 5 and implementing screening guidelines at 50 years of age could allow cases of ADH to progress to a higher stage lesion.
Future Directions and Recommendations
Foremost, the USPSTF needs to provide an addendum to its report that details its methodology in determining whether a rigorous systematic review was completed. A systematic review completed in stepwise fashion, as outlined by PRISMA or AMSTAR, needs to be published or executed so that the highest level of evidence is provided to imaging professionals, patients, and physicians. Next, the current report was enhanced with population modeling to determine whether screening mammography was a worthwhile endeavor. Because of the advancement in clinical practice and technology, these models of prediction should be based on evidence published beyond the use of FSM to accurately detect breast cancer, such as those clinical trials that are being conducted with digital mammography. In addition, a predictive algorithm needs to be clinically inclusive of the use of breast sonography and MRI to refine the suspicious areas found on the screening mammogram. An additional consideration identified by the task force was the potential for being "overdiagnosed," otherwise known as being treated for a cancer that will not appear during a woman's lifetime. 1 This concern was coupled with the variability in a radiologist's experience reading breast imaging studies, and currently this potential has been addressed by directing attention to interpretive volumes of the radiologist 9 and the use of computer-aided diagnosis (CAD). CAD highlights areas of irregular breast tissue on the imaging study, and studies have shown a 20% increase in sensitivity for radiologists with lower volume practices using CAD. 10 One positive response to this task force report is to execute a randomized control trial (as suggested by the USPSTF 1 ) to compare the detection rates between FSM and DM for women with dense breast tissue. A large study is currently being conducted by the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial (ACRIN-DMIST), which recruited 49,500 asymptomatic women for screening with both DM and FSM. Early results have been published about the detection rates across different types of equipment manufacturers and which rates seemed negligible, 11 and therefore it will be important to monitor future results from the study to determine if any conclusive evidence is found.
In addition to randomized trials, it would also be highly relevant to conduct a PRISMA-directed meta-analysis to determine the sensitivity and specificity of multimodality imaging approaches to the detection of breast cancer (i.e., DM, diagnostic mammography views, breast sonography, and sonography-guided breast biopsy). Berg et al.'s recent study 12 of adding breast sonography to screening mammography demonstrated an increase in the detection rate. Additional research is needed that looks at these combined imaging approaches. Randomized controlled trials are needed that focus on DM coupled with the utilization of CAD to increase the sensitivity of a radiologist's reading.
Another important point was the task force's concern for asymptomatic women at low risk for breast cancer; however, that can only be assessed with a well-researched risk model that can properly classify a patient. The Gail model, 13, 14 for gauging breast cancer risk assessment, is a highly researched risk assessment tool that can be used to assist asymptomatic women in determining their risk. Additional research on risk assessment has been published by Claus et al., [15] [16] [17] and drawing from this research can truly determine whether certain patients are being subjected to unnecessary testing and expense.
The controversy that has ensued has largely been due to the media's use of one of the USPSTF's recommendations and publicizing it out of context-FSM as a solo screening technique. Interestingly, the task force lists competing recommendations from other organizations such as the American College of Obstetrics and Gynecology, American College of Physicians, and the Canadian Task Force on Preventive Health Care. 1 
Conclusion
This evaluation points out flaws that render the USPSTF's recommendations obsolete. They fail to address current breast imaging practice and data that have been published about a multimodality approach for detecting a breast lesion. Patients rely on sonographers, mammographers, and physicians to offer reliable evidence-based practice guidelines to assist them in making the correct preventive health decision. A revised set of guidelines is needed to assist patients in making the best decision about participating in screening breast examinations. The most appropriate way to guarantee patients are receiving quality health care is to become adept at reviewing published research and implementing information that will change current practice patterns. Being diligent about monitoring and responding to media reports, which can distort research, requires that sonographers, mammographers, and physicians are good consumers of research. This allows practitioners to discern the highest level of published evidence and determine whether clinical practice should be changed.
